Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Linkesch, 1985, [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses]., Acta Med Austriaca, 12, 123 Gisslinger, 1989, Long-term interferon therapy for thrombocytosis in myeloproliferative diseases., Lancet, 1, 634, 10.1016/S0140-6736(89)92142-9 Silver, 2006, Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha., Cancer, 107, 451, 10.1002/cncr.22026 Heis, 1999, The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera., Eur J Haematol, 62, 27, 10.1111/j.1600-0609.1999.tb01110.x Baxter, 2005, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders., Lancet, 365, 1054, 10.1016/S0140-6736(05)71142-9 James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera., Nature, 434, 1144, 10.1038/nature03546 Kralovics, 2005, A gain-of-function mutation of JAK2 in myeloproliferative disorders., N Engl J Med, 352, 1779, 10.1056/NEJMoa051113 Levine, 2005, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis., Cancer Cell, 7, 387, 10.1016/j.ccr.2005.03.023 Kiladjian, 2006, High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a., Blood, 108, 2037, 10.1182/blood-2006-03-009860 Kiladjian, 2012, The spectrum of JAK2-positive myeloproliferative neoplasms., Hematology Am Soc Hematol Educ Prog, 561 Stein, 2013, Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms., J Interferon Cytokine Res, 33, 145, 10.1089/jir.2012.0120 Quintás-Cardama, 2009, Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera., J Clin Oncol, 27, 5418, 10.1200/JCO.2009.23.6075 Hasselbalch, 2011, A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms., Expert Rev Hematol, 4, 637, 10.1586/ehm.11.63 Talpaz, 2001, Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia., Blood, 98, 1708, 10.1182/blood.V98.6.1708 Alvarado, 2003, Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia., Cancer Chemother Pharmacol, 51, 81, 10.1007/s00280-002-0533-4 Langer, 2005, Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study., Haematologica, 90, 1333 Talpaz, 2005, Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia., Clin Cancer Res, 11, 6247, 10.1158/1078-0432.CCR-05-0882 Samuelsson, 2006, A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life., Cancer, 106, 2397, 10.1002/cncr.21900 Jabbour, 2007, PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study., Cancer, 110, 2012, 10.1002/cncr.23018 Kiladjian, 2008, Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera., Blood, 112, 3065, 10.1182/blood-2008-03-143537 Quintás-Cardama, 2013, Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a., Blood, 122, 893, 10.1182/blood-2012-07-442012 Kiladjian, 2011, The renaissance of interferon therapy for the treatment of myeloid malignancies., Blood, 117, 4706, 10.1182/blood-2010-08-258772 Silver, 2013, Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis., Expert Rev Hematol, 6, 49, 10.1586/ehm.12.69 Gisslinger, 1992, Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha., Clin Exp Immunol, 90, 363, 10.1111/j.1365-2249.1992.tb05852.x Crowley, 2006, Handbook of statistics in clinical oncology, 2nd ed Barosi, 2009, Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference., Blood, 113, 4829, 10.1182/blood-2008-09-176818